"Octreotide" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A potent, long-acting synthetic SOMATOSTATIN octapeptide analog that inhibits secretion of GROWTH HORMONE and is used to treat hormone-secreting tumors; DIABETES MELLITUS; HYPOTENSION, ORTHOSTATIC; HYPERINSULINISM; hypergastrinemia; and small bowel fistula.
- SMS 201-995
- SMS 201 995
- SMS 201995
- SM 201-995
- SM 201 995
- SM 201995
- Sandoz 201-995
- Sandoz 201 995
- Sandoz 201995
- Compound 201-995
- Compound 201 995
- Compound 201995
- SAN 201-995
- SAN 201 995
- SAN 201995
Below are MeSH descriptors whose meaning is more general than "Octreotide".
Below are MeSH descriptors whose meaning is more specific than "Octreotide".
This graph shows the total number of publications written about "Octreotide" by people in this website by year, and whether "Octreotide" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
|Year||Major Topic||Minor Topic||Total|
To return to the timeline, click here.
Below are the most recent publications written about "Octreotide" by people in Profiles.
Tipnis S, Rieter WJ, Henderson-Suite V, Gordon L. Risk of Radiation Exposure to Clinical Staff from Paracenteses of Large-Volume Chylous Ascites After 177Lu-DOTATATE Infusion. J Nucl Med Technol. 2022 Sep; 50(3):274-277.
Velez JC, Kadian M, Taburyanskaya M, Bohm NM, Delay TA, Karakala N, Rockey DC, Nietert PJ, Goodwin AJ, Whelan TP. Hepatorenal Acute Kidney Injury and the Importance of Raising Mean Arterial Pressure. Nephron. 2015; 131(3):191-201.
Rahimi RS, Guntipalli P, Rockey DC. Worldwide practices for pharmacologic therapy in esophageal variceal hemorrhage. Scand J Gastroenterol. 2014 Feb; 49(2):131-7.
Xu W, Burke JF, Pilla S, Chen H, Jaskula-Sztul R, Gong S. Octreotide-functionalized and resveratrol-loaded unimolecular micelles for targeted neuroendocrine cancer therapy. Nanoscale. 2013 Oct 21; 5(20):9924-33.
Burton F, Alkaade S, Collins D, Muddana V, Slivka A, Brand RE, Gelrud A, Banks PA, Sherman S, Anderson MA, Romagnuolo J, Lawrence C, Baillie J, Gardner TB, Lewis MD, Amann ST, Lieb JG, O'Connell M, Kennard ED, Yadav D, Whitcomb DC, Forsmark CE. Use and perceived effectiveness of non-analgesic medical therapies for chronic pancreatitis in the United States. Aliment Pharmacol Ther. 2011 Jan; 33(1):149-59.
Mahvi D. Defining, controlling, and treating a pancreatic fistula. J Gastrointest Surg. 2009 Jul; 13(7):1187-8.
Morgan KA, Adams DB. Management of internal and external pancreatic fistulas. Surg Clin North Am. 2007 Dec; 87(6):1503-13, x.
Schell SR, Camp ER, Caridi JG, Hawkins IF. Hepatic artery embolization for control of symptoms, octreotide requirements, and tumor progression in metastatic carcinoid tumors. J Gastrointest Surg. 2002 Sep-Oct; 6(5):664-70.
Johnston BT, Shils J, Leite LP, Castell DO. Effects of octreotide on esophageal visceral perception and cerebral evoked potentials induced by balloon distension. Am J Gastroenterol. 1999 Jan; 94(1):65-70.
Horn JD, Gordon BM, Gordon L, Spicer KM. Octreotide uptake in the head and neck. Semin Nucl Med. 1997 Jan; 27(1):79-81.